Report cover image

Liposomal and Lipid-based Nanoparticle Drug Industry Research Report 2025

Publisher APO Research, Inc.
Published Sep 17, 2025
Length 139 Pages
SKU # APRC20462680

Description

Summary

According to APO Research, The global Liposomal and Lipid-based Nanoparticle Drug market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.

North American market for Liposomal and Lipid-based Nanoparticle Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Liposomal and Lipid-based Nanoparticle Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Liposomal and Lipid-based Nanoparticle Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Liposomal and Lipid-based Nanoparticle Drug include Acrotech Biopharma, Alnylam, Bausch Health, Chiesi Farmaceutici, CSPC, Fudan-Zhangjiang, Gilead Sciences, Ipsen and Jazz, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Liposomal and Lipid-based Nanoparticle Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Liposomal and Lipid-based Nanoparticle Drug.
The Liposomal and Lipid-based Nanoparticle Drug market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Liposomal and Lipid-based Nanoparticle Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Liposomal and Lipid-based Nanoparticle Drug Segment by Company

Acrotech Biopharma
Alnylam
Bausch Health
Chiesi Farmaceutici
CSPC
Fudan-Zhangjiang
Gilead Sciences
Ipsen
Jazz
Kinyond
Leadiant Biosciences
Luye Pharma
Pacira
Sayre Therapeutics
TTY Biopharma
Zydus Cadila
Johnson & Johnson
Sun Pharmaceutical
Teva
Takeda
Liposomal and Lipid-based Nanoparticle Drug Segment by Type

Liposomes Drugs
Lipid Nanoparticle Drugs
Liposomal and Lipid-based Nanoparticle Drug Segment by Application

Hospital
Retail Pharmacy
Other
Liposomal and Lipid-based Nanoparticle Drug Segment by Application

Hospital
Retail Pharmacy
Other
Liposomal and Lipid-based Nanoparticle Drug Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Liposomal and Lipid-based Nanoparticle Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Liposomal and Lipid-based Nanoparticle Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Liposomal and Lipid-based Nanoparticle Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Liposomal and Lipid-based Nanoparticle Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.

Table of Contents

139 Pages
1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Liposomal and Lipid-based Nanoparticle Drug by Type
2.2.1 Market Value Comparison by Type (2020 VS 2024 VS 2031)
2.2.2 Liposomes Drugs
2.2.3 Lipid Nanoparticle Drugs
2.3 Liposomal and Lipid-based Nanoparticle Drug by Application
2.3.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
2.3.2 Hospital
2.3.3 Retail Pharmacy
2.3.4 Other
2.4 Assumptions and Limitations
3 Liposomal and Lipid-based Nanoparticle Drug Breakdown Data by Type
3.1 Global Liposomal and Lipid-based Nanoparticle Drug Historic Market Size by Type (2020-2025)
3.2 Global Liposomal and Lipid-based Nanoparticle Drug Forecasted Market Size by Type (2026-2031)
4 Liposomal and Lipid-based Nanoparticle Drug Breakdown Data by Application
4.1 Global Liposomal and Lipid-based Nanoparticle Drug Historic Market Size by Application (2020-2025)
4.2 Global Liposomal and Lipid-based Nanoparticle Drug Forecasted Market Size by Application (2026-2031)
5 Global Growth Trends
5.1 Global Liposomal and Lipid-based Nanoparticle Drug Market Perspective (2020-2031)
5.2 Global Liposomal and Lipid-based Nanoparticle Drug Growth Trends by Region
5.2.1 Global Liposomal and Lipid-based Nanoparticle Drug Market Size by Region: 2020 VS 2024 VS 2031
5.2.2 Liposomal and Lipid-based Nanoparticle Drug Historic Market Size by Region (2020-2025)
5.2.3 Liposomal and Lipid-based Nanoparticle Drug Forecasted Market Size by Region (2026-2031)
5.3 Liposomal and Lipid-based Nanoparticle Drug Market Dynamics
5.3.1 Liposomal and Lipid-based Nanoparticle Drug Industry Trends
5.3.2 Liposomal and Lipid-based Nanoparticle Drug Market Drivers
5.3.3 Liposomal and Lipid-based Nanoparticle Drug Market Challenges
5.3.4 Liposomal and Lipid-based Nanoparticle Drug Market Restraints
6 Market Competitive Landscape by Players
6.1 Global Top Liposomal and Lipid-based Nanoparticle Drug Players by Revenue
6.1.1 Global Top Liposomal and Lipid-based Nanoparticle Drug Players by Revenue (2020-2025)
6.1.2 Global Liposomal and Lipid-based Nanoparticle Drug Revenue Market Share by Players (2020-2025)
6.2 Global Liposomal and Lipid-based Nanoparticle Drug Industry Players Ranking, 2023 VS 2024 VS 2025
6.3 Global Key Players of Liposomal and Lipid-based Nanoparticle Drug Head Office and Area Served
6.4 Global Liposomal and Lipid-based Nanoparticle Drug Players, Product Type & Application
6.5 Global Liposomal and Lipid-based Nanoparticle Drug Manufacturers Established Date
6.6 Global Liposomal and Lipid-based Nanoparticle Drug Market CR5 and HHI
6.7 Global Players Mergers & Acquisition
7 North America
7.1 North America Liposomal and Lipid-based Nanoparticle Drug Market Size (2020-2031)
7.2 North America Liposomal and Lipid-based Nanoparticle Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 North America Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2020-2025)
7.4 North America Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2026-2031)
7.5 United States
7.5 United States
7.6 Canada
7.7 Mexico
8 Europe
8.1 Europe Liposomal and Lipid-based Nanoparticle Drug Market Size (2020-2031)
8.2 Europe Liposomal and Lipid-based Nanoparticle Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031
8.3 Europe Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2020-2025)
8.4 Europe Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2026-2031)
8.5 Germany
8.6 France
8.7 U.K.
8.8 Italy
8.9 Spain
8.10 Russia
8.11 Netherlands
8.12 Nordic Countries
9 Asia-Pacific
9.1 Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Size (2020-2031)
9.2 Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2020-2025)
9.4 Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2026-2031)
9.5 China
9.6 Japan
9.7 South Korea
9.8 India
9.9 Australia
9.10 China Taiwan
9.11 Southeast Asia
10 South America
10.1 South America Liposomal and Lipid-based Nanoparticle Drug Market Size (2020-2031)
10.2 South America Liposomal and Lipid-based Nanoparticle Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 South America Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2020-2025)
10.4 South America Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2026-2031)
10.5 Brazil
10.6 Argentina
10.7 Chile
10.8 Colombia
10.9 Peru
11 Middle East & Africa
11.1 Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size (2020-2031)
11.2 Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031
11.3 Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2020-2025)
11.4 Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2026-2031)
11.5 Saudi Arabia
11.6 Israel
11.7 United Arab Emirates
11.8 Turkey
11.9 Iran
11.10 Egypt
12 Players Profiled
12.1 Acrotech Biopharma
12.1.1 Acrotech Biopharma Company Information
12.1.2 Acrotech Biopharma Business Overview
12.1.3 Acrotech Biopharma Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2020-2025)
12.1.4 Acrotech Biopharma Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
12.1.5 Acrotech Biopharma Recent Developments
12.2 Alnylam
12.2.1 Alnylam Company Information
12.2.2 Alnylam Business Overview
12.2.3 Alnylam Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2020-2025)
12.2.4 Alnylam Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
12.2.5 Alnylam Recent Developments
12.3 Bausch Health
12.3.1 Bausch Health Company Information
12.3.2 Bausch Health Business Overview
12.3.3 Bausch Health Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2020-2025)
12.3.4 Bausch Health Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
12.3.5 Bausch Health Recent Developments
12.4 Chiesi Farmaceutici
12.4.1 Chiesi Farmaceutici Company Information
12.4.2 Chiesi Farmaceutici Business Overview
12.4.3 Chiesi Farmaceutici Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2020-2025)
12.4.4 Chiesi Farmaceutici Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
12.4.5 Chiesi Farmaceutici Recent Developments
12.5 CSPC
12.5.1 CSPC Company Information
12.5.2 CSPC Business Overview
12.5.3 CSPC Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2020-2025)
12.5.4 CSPC Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
12.5.5 CSPC Recent Developments
12.6 Fudan-Zhangjiang
12.6.1 Fudan-Zhangjiang Company Information
12.6.2 Fudan-Zhangjiang Business Overview
12.6.3 Fudan-Zhangjiang Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2020-2025)
12.6.4 Fudan-Zhangjiang Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
12.6.5 Fudan-Zhangjiang Recent Developments
12.7 Gilead Sciences
12.7.1 Gilead Sciences Company Information
12.7.2 Gilead Sciences Business Overview
12.7.3 Gilead Sciences Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2020-2025)
12.7.4 Gilead Sciences Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
12.7.5 Gilead Sciences Recent Developments
12.8 Ipsen
12.8.1 Ipsen Company Information
12.8.2 Ipsen Business Overview
12.8.3 Ipsen Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2020-2025)
12.8.4 Ipsen Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
12.8.5 Ipsen Recent Developments
12.9 Jazz
12.9.1 Jazz Company Information
12.9.2 Jazz Business Overview
12.9.3 Jazz Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2020-2025)
12.9.4 Jazz Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
12.9.5 Jazz Recent Developments
12.10 Kinyond
12.10.1 Kinyond Company Information
12.10.2 Kinyond Business Overview
12.10.3 Kinyond Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2020-2025)
12.10.4 Kinyond Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
12.10.5 Kinyond Recent Developments
12.11 Leadiant Biosciences
12.11.1 Leadiant Biosciences Company Information
12.11.2 Leadiant Biosciences Business Overview
12.11.3 Leadiant Biosciences Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2020-2025)
12.11.4 Leadiant Biosciences Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
12.11.5 Leadiant Biosciences Recent Developments
12.12 Luye Pharma
12.12.1 Luye Pharma Company Information
12.12.2 Luye Pharma Business Overview
12.12.3 Luye Pharma Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2020-2025)
12.12.4 Luye Pharma Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
12.12.5 Luye Pharma Recent Developments
12.13 Pacira
12.13.1 Pacira Company Information
12.13.2 Pacira Business Overview
12.13.3 Pacira Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2020-2025)
12.13.4 Pacira Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
12.13.5 Pacira Recent Developments
12.14 Sayre Therapeutics
12.14.1 Sayre Therapeutics Company Information
12.14.2 Sayre Therapeutics Business Overview
12.14.3 Sayre Therapeutics Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2020-2025)
12.14.4 Sayre Therapeutics Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
12.14.5 Sayre Therapeutics Recent Developments
12.15 TTY Biopharma
12.15.1 TTY Biopharma Company Information
12.15.2 TTY Biopharma Business Overview
12.15.3 TTY Biopharma Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2020-2025)
12.15.4 TTY Biopharma Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
12.15.5 TTY Biopharma Recent Developments
12.16 Zydus Cadila
12.16.1 Zydus Cadila Company Information
12.16.2 Zydus Cadila Business Overview
12.16.3 Zydus Cadila Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2020-2025)
12.16.4 Zydus Cadila Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
12.16.5 Zydus Cadila Recent Developments
12.17 Johnson & Johnson
12.17.1 Johnson & Johnson Company Information
12.17.2 Johnson & Johnson Business Overview
12.17.3 Johnson & Johnson Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2020-2025)
12.17.4 Johnson & Johnson Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
12.17.5 Johnson & Johnson Recent Developments
12.18 Sun Pharmaceutical
12.18.1 Sun Pharmaceutical Company Information
12.18.2 Sun Pharmaceutical Business Overview
12.18.3 Sun Pharmaceutical Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2020-2025)
12.18.4 Sun Pharmaceutical Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
12.18.5 Sun Pharmaceutical Recent Developments
12.19 Teva
12.19.1 Teva Company Information
12.19.2 Teva Business Overview
12.19.3 Teva Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2020-2025)
12.19.4 Teva Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
12.19.5 Teva Recent Developments
12.20 Takeda
12.20.1 Takeda Company Information
12.20.2 Takeda Business Overview
12.20.3 Takeda Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2020-2025)
12.20.4 Takeda Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
12.20.5 Takeda Recent Developments
13 Report Conclusion
14 Disclaimer
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.